Mariner’s Acadia Pharmaceuticals ACAD Stock Holding History

Mariner’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$340K	Buy	13,431 +1,913	+17%	+$42.1K	﹤0.01%	2746
2026 Q1	$257K	Sell	11,518 -12,639	-52%	-$302K	﹤0.01%	3014
2025 Q4	$645K	Buy	24,157 +9,514	+65%	+$227K	﹤0.01%	2266
2025 Q3	$312K	Buy	+14,643	New	+$346K	﹤0.01%	2772
2025 Q2	–	Sell	-18,190	Closed	-$302K	–	3471
2025 Q1	$302K	Buy	+18,190	New	+$330K	﹤0.01%	2616
2022 Q2	–	Sell	-11,415	Closed	-$277K	–	1372
2022 Q1	$277K	Buy	+11,415	New	+$276K	﹤0.01%	1303

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mariner's ACAD Position: Q2 2026 in Review

Mariner increased its Acadia Pharmaceuticals (ACAD) stake by 17% in Q2 2026, buying an estimated $42.1K and bringing the position to 13,431 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #2746.

Mariner first reported a position in ACAD in Q1 2022 and has held it in 6 quarters since. The position peaked at $645K in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Mariner held 13,431 shares of Acadia Pharmaceuticals worth $340K as of Q2 2026.
Mariner bought 1,913 Acadia Pharmaceuticals shares in Q2 2026, an estimated $42.1K.
Acadia Pharmaceuticals made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2746 holding.
Mariner first reported a position in Acadia Pharmaceuticals in Q1 2022 and has held it in 6 quarters since.
Mariner's Acadia Pharmaceuticals position peaked at $645K in Q4 2025.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.